Associate Professor of Obstetrics and Gynecology, Yale University
Obstetrics & Gynecology
Dr. Thomas J. Rutherford, MD
|
|
Give Review
Thomas Rutherford works in the field of Obstetrics & Gynecology. He graduated from University of Toledo College of Medicine. He received awards:"America's Top Doctors", "Top Doctors: New York Metro Area", "New York Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Most Compassionate Doctor" and "Fellow (FACOG)". Thomas J. Rutherford, MD is also published. He has 100 publications published. The lastest publication: "A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or prima...'
Publications
- Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube Cancers: A re...
- A Series of Malignant Ovarian Cancers Arising From Within a Mature Cystic Teratoma: A Single Institution Experience.
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube, or prima...
- Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis.
- Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterin...
- Feasibility, Sensitivity, and Specificity of Postprocedure Peritoneal Cytology.
- A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian Cancer.
- T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and Ovarian carcinosarcomas overexpressing HER2.
- Distinct mechanisms of Cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
- Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous Carcinoma in vitro and in vivo.
- Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian Cancer cell lines in vi...
- Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial Cancer in vitro and in vivo.
- Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous Carcinoma in vitro and in vivo.
- T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous Carcinoma in vitro and in vivo.
- Genotyping Diagnosis of Nongestational ChorioCarcinoma Involving Fallopian Tube and Broad Ligament: A Case Study.
- A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian Cancer.
- HER2/neu gene amplification determines the sensitivity of uterine serous Carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
- Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian Cancer patients treated with neoadj...
- Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian Cancer: implications for ovarian Cancer im...
- Tubulin-?-III overexpression by uterine serous Carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
- Class III ?-Tubulin Overexpression in Ovarian Clear Cell and Serous Carcinoma as a Marker for Poor Overall Survival after Platinum/Taxane Chemotherapy and Sensitivity ...
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous Carcinoma.
- Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian Cancer stem cells impacts differentiation and metastatic potential.
- Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian Cancer (FIGO Stage IIIC and IV).
- HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas.
- Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and Ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
- Uterine and Ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
- Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial Cancer.
- A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study.
- Her2/neu extracellular domain shedding in uterine serous Carcinoma: implications for immunotherapy with trastuzumab.
- The significance of perineural invasion in early-stage Cervical cancer.
- Prevalence of epithelial ovarian Cancer stem cells correlates with recurrence in early-stage ovarian Cancer.
- Long-term overweight and weight gain in early adulthood in association with risk of endometrial Cancer.
- Trop-2 overexpression in poorly differentiated endometrial endometrioid Carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
- MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian Cancer management.
- Cervical Carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 ...
- Tissue factor expression in ovarian Cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
- Expression of tissue factor in adenoCarcinoma and squamous cell Carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimer...
- Eradication of chemotherapy-resistant CD44+ human ovarian Cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
- Expression of αV-integrins in uterine serous papillary Carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integ...
- Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, o...
- Regulation of inflammation by the NF-κB pathway in ovarian Cancer stem cells.
- High-grade, chemotherapy-resistant primary ovarian Carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunoth...
- Uterine serous papillary Carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Tr...
- High-grade, chemotherapy-resistant ovarian Carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a ful...
- Primary cervical Carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclo...
- Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary Carcinoma cell lines with high versus low HER-2/neu expression in v...
- hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary Carcinoma.
- MicroRNA signatures differentiate uterine Cancer tumor subtypes.
- A KRAS-variant in ovarian Cancer acts as a genetic marker of Cancer risk.
- Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary Carcinoma cell lines with high vs low HER-2/neu expression in vitro.
- Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian Cancer.
- TWISTing stemness, inflammation and proliferation of epithelial ovarian Cancer cells through MIR199A2/214.
- HER-2/NEU overexpression in vulvar Paget Disease: the Yale experience.
- Serum amyloid A: a novel biomarker for endometrial Cancer.
- Cesarean scar ectopic pregnancy: case series and review of the literature.
- In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenoCarcinoma.
- HER-2/neu receptor gene Status in endometrial carcinomas: a tissue microarray study.
- Overexpression of EpCAM in uterine serous papillary Carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
- Serum amyloid A (SAA): a novel biomarker for uterine serous papillary Cancer.
- Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing aut...
- Ovarian preservation and staging in reproductive-age endometrial Cancer patients.
- Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian Cancer: implications for epithelial...
- Brain metastases in epithelial ovarian and primary peritoneal Carcinoma.
- Stathmin and tubulin expression and survival of ovarian Cancer patients receiving platinum treatment with and without paclitaxel.
- Liver metastasis in a case of adenoid cystic Carcinoma of the Bartholin''s gland: a rare presentation.
- Phenoxodiol: pharmacology and clinical experience in Cancer monotherapy and in combination with chemotherapeutic drugs.
- Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healt...
- Molecular phenotyping of human ovarian Cancer stem cells unravels the mechanisms for repair and chemoresistance.
- Benign multicystic mesothelioma: a case report of three sisters.
- Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian Cancer.
- Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian Cancer cells.
- Anti-tumor activity of phenoxodiol: from bench to clinic.
- The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies.
- Diagnostic markers for early detection of ovarian Cancer.
- Carcinosarcoma of the ovary.
- ERCC1 genotype and phenotype in epithelial ovarian Cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
- IGF-II promoter methylation and ovarian Cancer prognosis.
- Combined effect of packaging atmosphere and storage temperature on growth of Listeria monocytogenes on ready-to-eat shrimp.
- Macrophage migration inhibitory factor expression in ovarian Cancer.
- Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian Cancer and leads to improved survival in stage IV disease.
- MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian Cancer.
- Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.
- TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian Cancer.
- Molecular mechanism of phenoxodiol-induced apoptosis in ovarian Carcinoma cells.
- Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian Cancer cells.
- Improved survival in surgical stage I patients with uterine papillary serous Carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
- Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian Carcinoma.
- Serum protein markers for early detection of ovarian Cancer.
- Extrarenal Wilms'' tumor of the Uterine corpus.
- HOXA10 expression in endometrial adenoCarcinoma.
- Patients with uterine papillary serous Cancers may benefit from adjuvant platinum-based chemoradiation.
- Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous Carcinoma. Part I: morphologic features.
- Identification of differentially expressed genes in clinically distinct groups of serous ovarian Carcinomas using cDNA microarray.
- Apoptosis-based evaluation of chemosensitivity in ovarian Cancer patients.
- Resistance of ovarian Carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.
- The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation.
- Epithelial ovarian Cancer cells secrete functional Fas ligand.
- Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian Cancer cells.
Schools
University Of Toledo
Albert Einstein Med Center
Cooper Hospital Mc UMDNJ
Yale University School Of Med
Procedures Preformed
- Colpopexy
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors: New York Metro Area
- New York Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Most Compassionate Doctor
- Fellow (FACOG)
Education
-
Cooper University Hospital -
Albert Einstein Healthcare Network -
University of Toledo College of Medicine
Hospital
-
Yale-New Haven Hospital -
Danbury Hospital
Drug Facts
| NPI NUMBER | 1629068044 | |
| NPPES Provider LastName | RUTHERFORD | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 065191369 | |
| NPPES Provider State | CT | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 123.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629068044 |
| Last Name Of The Provider | RUTHERFORD |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Stephanie R. Vaz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter E. Schwartz, MD |
|
|
Dr. Aileen Gariepy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elena S. Ratner, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Aydin M. Arici, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Maria C. De Leon, MD |
|
|
Dr. Kimberly W. Keefe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alessandro Santin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea L. Hoboken, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine A. Laky, MD
This Doctor is OpenDoctor Recommended.
|